Effects of Ultraviolet B Exposure Using a Ultraviolet Skin Care Device on Vitamin D Production and Immune Response in Healthy Adults

Not Applicable

Completed

• Conditions: Skin Inflammation; Skin Melanoma
• Interventions: Device: Ultraviolet B exposure to produce vitamin D synthesis

• Registration Number: NCT06625918
• Lead Sponsor: Wonju Severance Christian Hospital

Brief Summary

Vitamin D regulates various physiological functions, including calcium homeostasis, bone health, and potentially reducing cancer risks. Its primary source is Ultraviolet B radiation, but factors like aging, skin type, and modern lifestyles limit sun exposure, leading to widespread deficiency. This study explores using a daily Ultraviolet B Light Emitting Diodes device to improve vitamin D levels while assessing the potential for skin inflammation.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-03-20
• Primary Completion: 2024-04-29
• Study Completion: 2024-09-30
• Status Verified: 2024-10
• Study First Submitted: 2024-10-02
• Study First Submitted QC: 2024-10-02
• Study First Posted: 2024-10-03
• Last Update Submitted: 2025-04-14
• Last Update Posted: 2025-04-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 27

Inclusion Criteria

Age ranges 19-65 years Healthy participants Patients who are willing or able to follow the doctor's instructions Fully understand the purpose and procedure of this clinical trial

Exclusion Criteria

Participants excluded those who have any kind of disease Lactating and pregnant women Physical disabilities that could interfere with participation, a history of depression, or other psychiatric conditions

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Single arm	Ultraviolet B exposure to produce vitamin D synthesis	Single group Treatment

Primary Outcome Measures

Name	Time	Method
Measurement of Total white blood cells its differential	2 weeks and 4 weeks	2 weeks and 4 weeks treatment of total white blood cells and its differential counts such as eosinophils, basophils, lymphocytes, etc from baseline

Secondary Outcome Measures

Name	Time	Method
Measurement of oxidative and inflammatory markers	2 weeks and 4 weeks	2 weeks and 4 weeks treatment of oxidative markers such as reactive oxygen species, nitric oxide, glutathione peroxidase, and inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, and IL-10, etc.

Trial Locations

Locations (1)

Prof. Kyu-Jae Lee, Ph.D.; 🇰🇷 Wŏnju, Gwando, Korea, Republic of